Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Mar 17;14:542–549.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Olomoucine treatment decreased localization of MMP-2 protein at the wound edge. A: MMP-2 immunofluorescence is elevated at the wound edge in untreated control corneas. B: The immunostaining of MMP-2 at the wound edge (arrow) is reduced in olomoucine-treated corneas. C: Whole mounted corneas without primary antibody showed no immunofluorescence. D: Paraffin sections of wounded control corneas showed MMP-2 immunofluorescence in all layers of the cornea at wound edge (arrow) and in basal epithelial cells distal to the wound (arrowhead). E: The paraffin section of olomoucine-treated cornea showed reduced immunofluorescence of MMP-2 at the wound edge (arrow). MMP-2 immunofluorescence persisted in the basal layers of epithelium (arrowhead). F: No immunostaining was detected in the paraffin section of the cornea when primary MMP-2 antibody was omitted. Scale bar=100 μM.